Succeeding where others failed, Watson Pharmaceuticals got the FDA go-ahead to sell a generic version of Johnson & Johnson's Duragesic pain patch. With the patch, Watson will be jumping into a $1.2 billion market now divided among Duragesic and several other generic competitors.
- check out the release on the approval
Related Articles:
Watson to pay $1.9B for Andrx. Report
Bisaro handed reigns at Watson. Report